{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:42:04Z","timestamp":1778629324521,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.003","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T14:05:35Z","timestamp":1269957935000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rituximab in Indolent Lymphomas"],"prefix":"10.1053","volume":"47","author":[{"given":"Tarek","family":"Sousou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.003_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib2","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/annonc\/mdf119","article-title":"Survival after progression in patients with follicular lymphoma: analysis of prognostic factors","volume":"13","author":"Montoto","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib5","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib8","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century","volume":"168","author":"Pulte","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib13","first-page":"486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F\/Up) of 7 years [abstract]","volume":"108","author":"Colombat","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib14","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/1097-0142(19870715)60:2<156::AID-CNCR2820600205>3.0.CO;2-K","article-title":"The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma","volume":"60","author":"Ezdinli","year":"1987","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","article-title":"Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma","volume":"16","author":"Hagenbeek","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/bjoc.2001.1822","article-title":"A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma","volume":"85","author":"Rohatiner","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma","volume":"61","author":"Steward","year":"1988","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib19","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02981940","article-title":"Re-treatment of relapsed indolent B-cell lymphoma with rituximab","volume":"73","author":"Igarashi","year":"2001","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib21","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib23","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib25","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/jco.2009.27.15_suppl.8512","article-title":"Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35\/98 [abstract]","volume":"27","author":"Ghielmini","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib26","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1200\/jco.2009.27.15_suppl.8534","article-title":"First results of long-term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/03 [abstract]","volume":"27","author":"Taverna","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib29","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib30","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1445-5994.2007.01338.x","article-title":"Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange","volume":"37","author":"Chow","year":"2007","journal-title":"Int Med J"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib32","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects","volume":"100","author":"Rose","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib33","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib36","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib37","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib39","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib40","first-page":"4612","article-title":"Timing of rituximab\/fludarabine in Waldenstrom's macroglobulinemia may avert hyperviscosity [abstract]","volume":"104","author":"Nichols","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib41","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib43","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib44","first-page":"836","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract]","volume":"112","author":"Van Oers","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib45","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11864-006-0037-2","article-title":"Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma","volume":"7","author":"Friedberg","year":"2006","journal-title":"Curr Treat Opt Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1046\/j.1365-2141.2002.03535.x","article-title":"Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma","volume":"117","author":"Friedberg","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib48","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","article-title":"Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response","volume":"10","author":"Gluck","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib49","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V99.1.67","article-title":"Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma","volume":"99","author":"Ansell","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.2009.07773.x","article-title":"Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma","volume":"146","author":"Friedberg","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib53","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-07-0815","article-title":"Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma","volume":"13","author":"Leonard","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2005.1.329","article-title":"Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy","volume":"2005","author":"Friedberg","year":"2005","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2010.01.003_bib55","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:14Z","timestamp":1758522014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0037196310000041"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in Indolent Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}